| Comparison of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with gadofosveset trisodium (Vasovist, Schering, Berlin, Germany) to gadopentetate dimeglumine (GD-DTPA, Magnevist, Schering) in the assessment of response to neo-adjuvant treatment with bevacizumab (Avastin) of liver metastases in patients with colorectal cancer | Comparison of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with gadofosveset trisodium (Vasovist, Schering, Berlin, Germany) to gadopentetate dimeglumine (GD-DTPA, Magnevist, Schering) in the assessment of response to neo-adjuvant treatment with bevacizumab (Avastin) of liver metastases in patients with colorectal cancer | EUCTR2006-005530-21-BE |
| Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases | Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions | NCT02967380 |
| Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction | Multicenter, Single-blind, Randomized, Intraindividual Study of the Safety and Efficacy of Magnevist Gadopentetate Dimeglumine (Magnevist® Injection) at 0.1 and 0.2 mmol/kg for the Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction | NCT00310544 |
| Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries | A Phase III, Comparative Multi-center Randomized Double-blind, Crossover Study of the Safety, Tolerability and Diagnostic Efficacy of Gadobenate Dimeglumine and Gadopentetate Dimeglumine in Magnetic Resonance Angiography of the Carotid, Renal/Abdominal and Peripheral Arteries | NCT01260636 |
